EU Heart Condition Warning For COVID-19 Vaccines Comirnaty And Spikevax
Capillary Leak Syndrome A Side-Effect Of Janssen Vaccine
Executive Summary
All four coronavirus vaccines authorized for marketing in the EU/European Economic Area have had their safety information updated because of various adverse events including myocarditis, pericarditis and capillary leak syndrome.
You may also be interested in...
COVID-19: EMA Says Guillain-Barré Syndrome Is A Side-Effect Of AZ’s Vaxzevria
The EU’s pharmacovigilance committee has recommended safety updates for two COVID-19 vaccines, and is keeping its eye on a range of possible side-effects with all four authorized products.
Coronavirus Notebook: Janssen Vaccine Effective Against Two Virus Variants In South Africa Study, But Gets EU Thrombocytopenia Warning
Data show that more than 480 million COVID-19 vaccines have now been administered in the EU/European Economic Area, with Malta, Iceland and Ireland leading the way in the percentage of people now fully vaccinated.
Coronavirus Notebook: EMA OKs More Vaccine Production Plants, WHO Sounds Alert Over Africa
Vaxzevria should not be given to people who have had capillary leak syndrome, the EU regulator says. The G7 leaders have made big pledges on vaccine donations, and international regulatory bodies have issued a guide to shoring up confidence in vaccination.